The investigation centers on claims that Corcept Therapeutics misled shareholders about the status of relacorilant, a treatment under development for Cushing’s syndrome. While the company publicly emphasized the drug's path toward FDA approval, a federal securities lawsuit alleges that management failed to disclose critical feedback from regulators questioning the adequacy of the clinical development program. This omission purportedly masked a material risk that the New Drug Application would face rejection.

Shareholders currently holding CORT are encouraged to reach out to attorney Sophia Anne Silayan to discuss potential legal avenues. Kuehn Law has stated it covers all case costs for clients, though investors are advised to act promptly to preserve their rights in the ongoing derivative litigation.